AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
Latest, Q2 2026
1,140
Period ended Jun 30, 2026
Change on a year earlier
-2.2%
1,166 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
39
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Raw Materials ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,140 | -2.2% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,106 | -0.5% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,084 | +2.6% | Form 10-Q (filed 2026-08-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,082 | +4.8% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,166 | +6.1% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,111 | +1.3% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,057 | -3.9% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,032 | -17.8% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,099 | -13.6% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,097 | -8.7% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,100 | +10.0% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,256 | +30.8% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,272 | +28.7% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,202 | +16.9% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,000 | -0.3% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2022 | Sep 30, 2022 | 960 | +8.0% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 988 | +13.0% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,028 | +24.5% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,003 | +26.8% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2021 | Sep 30, 2021 | 889 | +21.0% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 874 | +20.1% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2021 | Mar 31, 2021 | 826 | +125.7% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 791 | +104.9% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2020 | Sep 30, 2020 | 735 | +104.2% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 728 | +152.8% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 366 | +53.1% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 386 | +43.0% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2019 | Sep 30, 2019 | 360 | +71.4% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 288 | +50.8% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 239 | +23.8% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2018 | Dec 31, 2018 | 270 | +56.1% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2018 | Sep 30, 2018 | 210 | +30.4% | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2018 | Jun 30, 2018 | 191 | +33.6% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 193 | +48.5% | Form 10-Q (filed 2018-05-04) ↗ |
| Q4 2017 | Dec 31, 2017 | 173 | +22.7% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 161 | +22.9% | 10-Q FY2017 (XBRL) ↗ |
| Q2 2017 | Jun 30, 2017 | 143 | +8.3% | 10-Q FY2017 (XBRL) ↗ |
| Q1 2017 | Mar 31, 2017 | 130 | -16.1% | 10-Q FY2017 (XBRL) ↗ |
| Q4 2016 | Dec 31, 2016 | 141 | -16.6% | Form 10-K (filed 2018-02-16) ↗ |
| Q3 2016 | Sep 30, 2016 | 131 | -5.1% | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 132 | +4.8% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 155 | -4.9% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | 169 | – | Form 10-K (filed 2017-02-17) ↗ |
| Q3 2015 | Sep 30, 2015 | 138 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 126 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 163 | – | 10-Q FY2015 (XBRL) ↗ |
Cite this data
StockData. (2026). AbbVie Raw Materials ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/inv_raw
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.